Kawasaki Disease and Clinical Outcome Disparities Among Black Children

Luz A Padilla1, Jacqueline L Collins2, Adeniyi J Idigo1

  • 1Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.

The Journal of Pediatrics
|September 27, 2020
PubMed

Insights

Black children with Kawasaki disease experienced worse outcomes, including lower treatment response and more persistent coronary artery abnormalities. This highlights potential racial disparities in Kawasaki disease management and long-term health.

Area of Science:

  • Pediatrics
  • Cardiology
  • Health Disparities

Background:

  • Kawasaki disease is a leading cause of acquired heart disease in children.
  • Understanding racial disparities in Kawasaki disease is crucial for equitable healthcare.
  • Previous research has not fully elucidated differences in outcomes between Black and White children.

Purpose of the Study:

  • To investigate racial disparities in Kawasaki disease prevalence.
  • To assess differences in disease sequelae between Black and White children.
  • To compare the effectiveness of intravenous gamma globulin (IVIG) treatment in Black versus White children.

Main Methods:

  • Retrospective analysis of electronic medical records from 2000-2015.
  • Inclusion of children diagnosed and treated for Kawasaki disease per American Heart Association criteria.
  • Comparison of demographic, clinical, laboratory, and echocardiographic data between Black and White patients.

Main Results:

  • Black children showed lower response rates to IVIG treatment within 10 days of fever onset (86.6% vs 95.6%).
  • Black children experienced longer hospitalizations and required more ancillary treatments.
  • A higher proportion of Black children had persistent coronary artery abnormalities at follow-up echocardiograms (21.2% vs 6.9% at third follow-up).

Conclusions:

  • Black children with Kawasaki disease exhibit higher IVIG-refractory rates and more severe inflammatory markers.
  • Despite similar initial treatment timing, Black children had a greater risk of persistent coronary artery abnormalities.
  • Findings suggest significant racial disparities in Kawasaki disease outcomes, necessitating further investigation and targeted interventions.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
402
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
165
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
144
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.1K